At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 495 enrolled
Drug / intervention
Lafutidine +2 moredrug
Likely dose
Lafutidine 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Koran Erosive Esophagitis Patients
In Brief
A Phase 3 clinical trial evaluating Lafutidine, Famotidine, and 1 other intervention for Erosive Esophagitis. Completed, enrolled 495 participants.
Detailed Summary
To evaluate the healing rate and safety of Lafutidine in erosive esophagitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsErosive Esophagitis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2011
First PostedDec 2011
Primary CompletionNov 2012
TodayJul 2026
First PostedDec 26, 2011
Enrollment StartNov 1, 2011
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 14.5 years ago
Interventions
Lafutidinedrug
Lafutidine 20mg/day
Famotidinedrug
Famotidine 40mg/day
Omeprazoledrug
Omeprazole 20mg/day